Thilo Schroeder

Managing Partner at Nextech Invest

Thilo Schroeder, Ph.D. has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality. Since 2012, Thilo has helped grow and shape Nextech as a leading oncology focused venture firm.

Thilo is a board member of Revolution Medicines (NASDAQ: RVMD), PMV Pharma (NASDAQ: PVMP), Circle Pharma, Silverback Therapeutics (NASDAQ: SBTX), MOMA Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC), Peloton Therapeutics (acquired by Merck) and IDEAYA Biosciences (NASDAQ: IDYA). Thilo is a past board observer of BlackDiamond Therapeutics (NASDAQ: BDTX).

Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX:MOLN).


Previous companies

IDEAYA Biosciences logo


  • Managing Partner

    Current role

  • Partner

View in org chart